Zepbound for Sleep Apnea: What Insurance Coverage Actually Looks Like

Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity. That approval changed how the coverage question gets asked, because many plans handle a drug differently once it carries an indication that is not weight loss. It did not make coverage automatic. Prior authorization, formulary placement and documentation still decide the outcome, and they vary plan by plan.

What the FDA actually approved

In December 2024, the FDA approved a supplement to the Zepbound application that added an obstructive sleep apnea indication. The current prescribing information lists the drug as indicated, in combination with a reduced-calorie diet and increased physical activity, "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."

Two details matter for coverage. First, the indication is written for adults who have obesity as well as moderate to severe OSA, so a plan reviewing the request will usually want both documented. Second, the label sets specific maintenance doses for the sleep apnea indication, which is relevant when a plan applies quantity limits.

You can read the current indication yourself on the FDA-approved prescribing information posted on DailyMed. Labels are revised, so check the current version rather than a summary of it. For background on the condition itself, the National Heart, Lung, and Blood Institute overview of sleep apnea is a good plain-language starting point.

Worth saying plainly: medication is one part of sleep apnea care, not a replacement for the rest of it. Positive airway pressure therapy, oral appliances and surgical options are still on the table, and your sleep clinician is the person to weigh them with.

Why a sleep apnea indication changes the coverage conversation

Plenty of people with obesity have run into the same wall. The plan covers the drug class in theory, then the pharmacy benefit turns out to carve out medications used for weight loss. That carve-out is common, and for years it was the end of the conversation for anti-obesity medicines.

A second labeled indication changes the shape of the request. When a drug has an approved use that is something other than weight loss, the review is no longer only about a weight-loss exclusion. It becomes a question of whether the plan covers the drug for that other indication, and whether your documentation meets its criteria.

This is why the wording on a denial letter matters so much. A denial that cites a blanket weight-loss exclusion is worth reading closely, because the request you are making may not be a weight-loss request at all. That is a point your prescriber can raise on your behalf. It is not a guarantee of a different result.

What plans typically ask for

Requirements vary by insurer, by employer group inside the same insurer, and by plan year. The pattern below is common, but it is not universal, and none of it should be read as a prediction about your plan.

Insurers such as UnitedHealthcare, CVS Caremark, Aetna, Express Scripts, Cigna and the Blue Cross Blue Shield plans all publish criteria documents, and those are the right place to look rather than a forum post. Formularies change, often quarterly, and two people with the same insurer card can have different coverage because their employers bought different plans. Check yours.

Medicare, specifically

Medicare Part D has long excluded drugs when they are used for weight loss. Historically, anti-obesity medicines have been coverable under Part D only when used for another medically accepted indication, which generally means an indication on the FDA-approved label. A labeled sleep apnea indication falls into that category, which is why the December 2024 change was significant for Medicare beneficiaries in particular.

What that does not mean is that every Part D plan pays. Plan sponsors still set formularies and utilization management, so coverage, tier and prior authorization requirements differ. Lilly's own coverage page makes the same point, noting that Medicare coverage can vary by condition.

Separately, CMS is running a short-term demonstration called the Medicare GLP-1 Bridge. It runs from July 1, 2026 through December 31, 2027, and sets a $50 copay for eligible Part D beneficiaries getting certain GLP-1 drugs. Read the fine print before counting on it. The Bridge operates outside the Part D benefit. The Part D deductible does not apply, the copay does not count toward your true out-of-pocket costs, and no low-income subsidy is attached. Lilly describes Bridge access to Zepbound as being for weight management, so it does not replace a coverage decision on the sleep apnea indication. Beneficiaries can check eligibility at Medicare.gov or by calling 1-800-MEDICARE.

If the answer comes back no

A first denial is not the end of the process, and it is more common than people expect. In general terms, and always subject to your own plan's rules and deadlines:

• Read the denial letter properly. It has to state a reason and it has to state your appeal rights and the deadline. The reason tells you what to fix.
• Check whether the right indication was submitted. A request processed as a weight-loss request may need to be resubmitted against the sleep apnea criteria with the supporting records attached.
• Ask about a formulary exception. Plans typically have a defined process for requesting coverage of a drug that is excluded or non-preferred.
• Ask your prescriber about a peer-to-peer review. This is a direct clinical conversation between your prescriber and the plan's reviewer, and it is often faster than paperwork alone.
• Use the internal appeal, then the external review. Most plans have a multi-level internal appeal, and many members also have a right to independent external review afterward.
• Keep a paper trail. Dates, reference numbers, names. It matters if the case goes further.

None of this predicts an outcome, and none of it is legal advice. It is the ordinary sequence, and knowing it makes the process less bewildering.

What it costs if coverage does not come through

Manufacturer pricing and savings terms change often, so treat any figure you read anywhere, including here, as a starting point to verify. The following are published by Lilly on its own Zepbound savings and insurance page and were checked there on September 1, 2026:

• $25 for up to a 3-month prescription of the single-dose pen, through the Zepbound Savings Program, for eligible patients with commercial insurance that covers Zepbound. Eligibility and terms apply.
• $299 per month for a 1-month prescription of the KwikPen or four vials, for eligible patients with commercial insurance that does not cover Zepbound. Terms apply.
• $299 per month as the self-pay starting price for the KwikPen or four vials.
• No more than $50 per month for eligible Medicare Part D patients through the Medicare GLP-1 Bridge, which Lilly describes as being for weight management. Not a guarantee of coverage.

Two things Lilly's own terms flag and people miss: government beneficiaries are excluded from the commercial savings card, and coverage can differ if you have Medicaid, VA, DOD or TRICARE benefits. Confirm current terms directly with Lilly and with your plan before you build a budget around a number.

The options people actually weigh

Most people in this situation are choosing between a handful of imperfect paths, not one obvious answer:

• Work the coverage path. Get the criteria document, get the sleep study and weight documentation into the request, and appeal if the first answer is no. This is slow and it is usually the highest-value option.
• Use the manufacturer savings program if you have commercial insurance and you meet Lilly's eligibility terms.
• Pay cash through the manufacturer's own pharmacy at the published self-pay price if coverage is not available to you.
• Revisit the rest of sleep apnea care with your sleep clinician. Airway pressure therapy, oral appliances and surgical options exist, and some of them are covered when a medication is not.
• Separate the two goals. Sleep apnea treatment and weight management are related but they are not the same purchase, and they do not have to be solved by the same product.

If cost is the wall you keep hitting, our guides to tirzepatide costs without insurance and tirzepatide pricing generally lay out the cash-pay landscape in more detail.

Where compounded medication does not fit

This needs to be unambiguous, because it is the question that brings people to a site like ours.

Compounded tirzepatide is not FDA-approved for obstructive sleep apnea. It is not FDA-approved for any indication. The FDA has not reviewed compounded preparations for safety, effectiveness or quality. A compounded preparation is not a generic version of Zepbound, and no generic Zepbound exists. It is a different preparation of the same active ingredient, made by a compounding pharmacy and prescribed at a licensed clinician's discretion. The FDA explains the distinction on its own drug compounding questions and answers page.

telos rx offers compounded tirzepatide for weight management only. It is not offered as a treatment for sleep apnea, it is not prescribed for sleep apnea, and it is not a back route to the approved product. If sleep apnea is what you are trying to treat, the right path is your own physician or sleep specialist, and the approved product pursued through your insurer. If you want to understand what compounded medication is and is not, our explainer on compounded semaglutide covers the same ground for the other molecule.

Frequently Asked Questions

Is Zepbound FDA-approved for sleep apnea?

Yes. The FDA approved a supplement adding the indication in December 2024. The current prescribing information lists Zepbound as indicated, alongside a reduced-calorie diet and increased physical activity, to treat moderate to severe obstructive sleep apnea in adults with obesity. Labels are revised over time, so confirm the current version on DailyMed.

Will my insurance cover Zepbound for sleep apnea?

No one can answer that from the outside, and anyone who tells you otherwise is guessing. Coverage depends on your specific plan's formulary and prior authorization criteria, which vary by insurer, by employer group and by plan year. Pull your plan's current drug list and its published criteria document, then work the request with your prescriber.

Does Medicare cover Zepbound for obstructive sleep apnea?

Medicare Part D excludes drugs used for weight loss, but anti-obesity medicines have generally been coverable when used for another medically accepted indication, which typically means an FDA-labeled one. A sleep apnea indication falls into that category. Individual Part D plans still set their own formularies and prior authorization rules, so check your plan directly and at Medicare.gov.

What does Zepbound cost if my plan does not cover it?

On its own savings and insurance page, checked on September 1, 2026, Lilly lists a self-pay starting price of $299 per month for the KwikPen or four vials. The same $299 monthly figure applies to eligible commercially insured patients whose plan does not cover Zepbound. Where a commercial plan does cover it, eligible patients may pay as little as $25 for up to a 3-month prescription of the single-dose pen. Terms apply and prices change, so verify with Lilly.

What can I do if my prior authorization is denied?

Read the denial letter for the stated reason and your appeal deadline. Check that the request was submitted against the right indication and with your sleep study and weight documentation attached. Then consider a formulary exception request, a peer-to-peer review between your prescriber and the plan, and your internal appeal followed by external review. This is general information about how the process usually runs, not legal advice or a prediction.

Is compounded tirzepatide an option for sleep apnea?

No. Compounded tirzepatide is not FDA-approved for obstructive sleep apnea, and it is not FDA-approved for any indication. The FDA has not reviewed compounded preparations for safety, effectiveness or quality, and a compounded preparation is not a generic version of Zepbound. telos rx offers compounded tirzepatide for weight management only. If you are seeking treatment for sleep apnea, discuss it with your own physician or sleep specialist and pursue the approved product through your insurer.

Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. TelosRX is not affiliated with, endorsed by or sponsored by either company, and does not sell, supply or distribute their products. TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality; they are prepared by licensed compounding pharmacies under federal compounding regulations. TelosRX offers compounded tirzepatide and semaglutide for weight management only, and does not treat obstructive sleep apnea. Any prescription is subject to evaluation by a licensed provider, and approval is not guaranteed. TelosRX does not accept or bill insurance. Prices and manufacturer savings terms cited here were verified on September 1, 2026 and change frequently; verify them at the source. This article is general information, not medical, insurance or legal advice. Individual results vary.

Read more about weight management options at telos rx.